Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
NCT02909933 on ClinicalTrials.gov · last registry update 2016-09-21
A small phase 4 — 30 participants, against a typical 75. The sponsor logged completion for October 2015. Primary outcome, as filed: The main outcome was change in body weight. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor type
- Other
- Enrollment
- 30
- Started
- 2015-07
- Primary completion
- 2015-10 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The main outcome was change in body weight.
Conditions studied
Polycystic Ovary Syndrome · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.